YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China

Inclusion Criteria: * Signed and dated informed consent * Chinese female subjects requesting oral contraception, including subjects who underwent abortion (medical or surgical) * Planned use of combined oral contraceptives for at least 6 cycles * Age: 18 to 45 years (inclusive); smokers must not be older than 35 years at the time of informed consent * At least 4 weeks postpartum for women who are not breastfeeding or after a second trimester abortion Exclusion Criteria: * Evidence or suspicion of incomplete abortion (medical abortion subjects must have complete abortion confirmed by ultrasound \[endometrial thickness ≤ 15 mm\]). * Pregnancy or lactation * Menstrual disorders consistent with ovarian failure (eg, oligomenorrhea, amenorrhea, hypomenorrhea) * Abuse of alcohol, drugs, or medicine (eg, laxatives) * Inability to cooperate with the study procedures for any reason (eg, language comprehension, psychiatric illness, inability to get to the study site). * Any diseases or conditions that can compromise the function of body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication * Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results * Any contraindication to YAZ according to the Chinese label, such as: * Renal impairment * Adrenal insufficiency * A high risk of arterial or venous thromboembolic diseases. Examples include subjects who are known to: * Have deep vein thrombosis or pulmonary embolism, now or in the past * Have cerebrovascular disease * Have coronary artery disease * Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) * Have inherited or acquired hypercoagulopathies * Have uncontrolled hypertension * Have diabetes mellitus with vascular disease * Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 * Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past * Liver tumors, benign or malignant, or liver disease * Hypersensitivity to any ingredient of the study drug * Undiagnosed abnormal genital bleeding * Sterilized subjects or concomitant use of other hormonal contraception, intrauterine device (IUD), or intrauterine system (IUS) during the study * For subjects qualifying for the moderate acne subgroup: * Subjects with acne and atopy, comedonal acne or acne conglobata, sandpaper acne or acne with multiple large nodes, cysts, fistular comedones, or abscessing fistular ducts * Use of preparations that have an acne-inducing effect (eg, iodinated or bromated drugs, tuberculostatics, lithium, vitamin B1 \[\>1.5 mg daily\], B6 \[\>2 mg daily\], B12 \[\>6 µg daily\], corticoids, adrenocorticotropic hormone anabolics, quinine, disulfiram, methoxypsoralene, phenobarbital, phenytoin, trimethadione, thyroid depressants, and certain oily cosmetics) * Subjects undergoing systemic acne treatment